Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells

Medicine and Dentistry

• Platelet 100%
• Cyclooxygenase 2 90%
• Galectin 3 54%
• Cells 36%
• Messenger RNA 27%
• Mesenchymal-Epithelial Transition 27%
• Cancer Cell 18%
• Collagen 18%
• Prostaglandin E2 18%
• Colon Carcinoma 18%
• Carcinoma Cell 18%
• Rofecoxib 18%
• Colon Cancer 9%
• Tumor Cell 9%
• Gene Expression 9%
• Prothrombin 9%
• Protein 9%
• Metastatic Carcinoma 9%
• Lactose 9%
• Carcinogenesis 9%
• down Regulation 9%
• Protein Synthesis 9%
• Prostanoid 9%
• Antibody 9%
• Binding Site 9%
• P21 9%
• Upregulation 9%
• Platelet Derived Growth Factor 9%
• Cyclooxygenase 2 Inhibitor 9%
• Cell Interaction 9%
• Cell Contact 9%
• Marker Gene 9%
• Inpatient 9%
• Marker 9%
• Cancer 9%

Biochemistry, Genetics and Molecular Biology

• Platelet 100%
• Cyclooxygenase 90%
• Galectin-3 54%
• Colon 27%
• Mesenchymal-Epithelial Transition 27%
• Collagen Receptor 27%
• Messenger RNA 27%
• Cancer Cell 18%
• Prostaglandin E2 18%
• Rofecoxib 18%
• Collagen 18%
• Gene Expression 9%
• Upregulation 9%
• down Regulation 9%
• Lactose 9%
• Carcinogenesis 9%
• Synthesis 9%
• Binding Site 9%
• Galactose 9%
• Protein Biosynthesis 9%
• P21 9%
• Cell Contact 9%
• Cell-Cell Interaction 9%
• GPVI 9%
• Marker Gene 9%
• Thrombocyte Adhesion 9%
• Galectin 9%
• Platelet-Derived Growth Factor 9%
• Animal Models 9%
• Protein 9%
• Antibody 9%
• Prostanoid 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Cyclooxygenase 2 90%
• Galectin 3 54%
• Messenger RNA 27%
• Collagen 18%
• Prostaglandin E2 18%
• Rofecoxib 18%
• Colon Carcinoma 18%
• Protein 9%
• Metastasis 9%
• Prostanoid 9%
• Carcinogenesis 9%
• Antibody 9%
• Binding Site 9%
• Platelet Derived Growth Factor 9%
• Prothrombin 9%
• Colon Cancer 9%
• Lactose 9%
• Animal 9%